Expression of CA-IX is associated with advanced stage tumors and poor survival in oral squamous cell carcinoma patients

Journal of Oral Pathology and Medicine

Volumn 41, Issue 9, 2012, Pages 667-674

  Pérez Sayáns, Mario ^b   Suárez Peñaranda, José Manuel ^a   Pilar, Gayoso Diz ^b   Supuran, Claudiu T ^c   Pastorekova, Silvia ^d   Barros Angueira, Francisco ^a   Gándara Rey, José Manuel ^e   García García, Abel ^b  

^a Instituto de Salud Carlos III   (Spain)

^b Santiago University Clinical Hospital   (Spain)

^c UNIVERSITY OF FLORENCE   (Italy)

^d INSTITUTE OF VIROLOGY   (Slovakia)

^e UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

CA IX; Carbonic anhydrases; Hypoxia; Oral squamous cell carcinoma; Tissue microarray

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; CELL MEMBRANE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MOUTH NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866851436     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2012.01147.x     Document Type: Article

References (44)

1. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381: 335-54.
2. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9(Suppl 5): 10-7.
3. Osinsky S, Zavelevich M, Vaupel P. Tumor hypoxia and malignant progression. Exp Oncol 2009; 31: 80-6.
4. Vaupel P. Metabolic microenvironment of tumor cells: a key factor in malignant progression. Exp Oncol 2010; 32: 125-7.
5. Le QT. Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches. Int J Radiat Oncol Biol Phys 2007; 69(Suppl 2): S56-8.
6. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008; 7: 168-81.
7. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
8. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004; 23: 293-310.
9. Vigneswaran N, Wu J, Song A, Annapragada A, Zacharias W. Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Exp Mol Pathol 2011; 90: 215-25.
10. Evans SM, Hahn S, Pook DR, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 2000; 60: 2018-24.
11. Raleigh JA, Calkins-Adams DP, Rinker LH, et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 1998; 58: 3765-8.
12. Gleadle JM, Ratcliffe PJ. Hypoxia and the regulation of gene expression. Mol Med Today 1998; 4: 122-9.
13. Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A. Hypoxia-inducible factors in OSCC. Cancer Lett 2011; 313: 1-8.
14. Supuran CT. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Future Med Chem 2011; 3: 1165-80.
15. Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011; 10: 767-777.
16. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995; 64: 375-401.
17. Potter CP, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003; 89: 2-7.
18. Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2003; 13: 1005-9.
19. Vullo D, Innocenti A, Nishimori I, et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs? Bioorg Med Chem Lett 2005; 15: 963-9.
20. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Reboiras-Lopez MD, Gandara Rey JM, Garcia-Garcia A. Genetic and molecular alterations associated with oral squamous cell cancer (Review). Oncol Rep 2009; 22: 1277-82.
21. American Joint Committee on Cancer. Chapter 3. Lip and oral cavity. In: Edge SB, Fritz AG, Byrd DR, Greene FL, Trotti A III, Compton CC, eds. Cancer Staging Manual, 7th edn. Chicago, IL: Springer, 2010; 1-4.
22. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
23. Pastorekova S, Zavadova Z, Kostal M, Babusikova O, Zavada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992; 187: 620-6.
24. Kivela AJ, Parkkila S, Saarnio J, et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol 2000; 114: 197-204.
25. Zat'ovicova M, Tarabkova K, Svastova E, et al. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods 2003; 282: 117-34.
26. a edn, Lyon: IARCPress, 2005; 177-80.
27. R Development Core Team. R: A Language and Environment for Statistical Computing [article online], 2009. Vienna, Austria: R Foundation for Statistical Computing. ISBN 3-900051-07-0. 2011; Available at: http://www.R-project.org (accessed on 21 October 2011.
28. Brewer CA, Liao SY, Wilczynski SP, et al. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol Oncol 1996; 63: 337-44.
29. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001; 61: 7992-8.
30. Klatte T, Belldegrun AS, Pantuck AJ. The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. BJU Int 2008; 101(Suppl 4): 45-8.
31. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001; 19: 3660-8.
32. Turner JR, Odze RD, Crum CP, Resnick MB. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum Pathol 1997; 28: 740-4.
33. Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 1998; 153: 279-85.
34. Choi SW, Kim JY, Park JY, Cha IH, Kim J, Lee S. Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Hum Pathol 2008; 39: 1317-22.
35. Roh JL, Cho KJ, Kwon GY, et al. The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol 2009; 45: 63-8.
36. Oliveira LR, Ribeiro-Silva A. Prognostic significance of immunohistochemical biomarkers in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2011; 40: 298-307.
37. Eckert AW, Lautner MH, Schutze A, Taubert H, Schubert J, Bilkenroth U. Coexpression of hypoxia-inducible factor-1 alpha and glucose transporter-1 is associated with poor prognosis in oral squamous cell carcinoma patients. Histopathology 2011; 58: 1136-47.
38. Kondo Y, Yoshikawa K, Omura Y, et al. Clinicopathological significance of carbonic anhydrase 9, glucose transporter-1, Ki-67 and p53 expression in oral squamous cell carcinoma. Oncol Rep 2011; 25: 1227-33.
39. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 2001; 7: 3399-403.
40. Le QT, Kong C, Lavori PW, et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2007; 69: 167-75.
41. Eckert AW, Lautner MH, Schutze A, et al. Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med 2010; 39: 313-7.
42. Kim SJ, Shin HJ, Jung KY, et al. Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol 2007; 37: 812-9.
43. Hoogsteen IJ, Marres HA, Wijffels KI, et al. Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res 2005; 11: 97-106.
44. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002; 62: 7066-74.